Study | Place | Conditions | Participants numbers | Interventions details | Total number of treatments | Age (years) | Female sex, no. (%) | BCVA at baseline | CST/CMT (μm) at baseline | Follow-up duration (months) |
---|---|---|---|---|---|---|---|---|---|---|
Gillies et al. 2014 < The BEVORDEX Study> [23] | Australia | DR | DEX: 46 IVB: 42 | DEX: 0.7 mg every 16 weeks + PRN IVB: 0.5 mg every 4 weeks + PRN | DEX: 2.7 IVB: 8.6 | DEX: 61.4 ± 9.0 IVB: 62.2 ± 10.5 (P = 0.71) | DEX: 16 (35%) IVB: 16 (38%) (P = 0.83) | DEX: 55.5 ± 12.5 IVB: 56.3 ± 11.9 (P = 0.75) | DEX: 474.3 ± 95.9 IVB: 503 ± 140.9 (P = 0.38) | 12 |
Allergan 2015 [27] | Multiple countries: Belgium, Denmark, France, Germany, Israel, Italy, Netherlands, Portugal, South Africa, Spain, United Kingdom, United States | DR | DEX: 181 IVR: 182 | DEX: 0.7 mg on Day 1, Month 5, and Month 10 IVR: 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression | NA | NA | DEX: 69 (38%) IVR: 66 (36%) | DEX: 60.2 ± 9.74 IVR: 60.4 ± 9.34 | DEX: 465.1 ± 136.09 IVR: 471.2 ± 139.51 | 12 |
Shah et al. 2016 [24] | Indiana, United States | DR | DEX: 27 IVB: 23 | DEX: 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections IVB: 1.25 mg given monthly during a 6 month period | DEX: 2.7 ± 0.5 IVB: 7.0 ± 0.2 (P < 0.001) | DEX: 65 ± 11 IVB: 61 ± 9 (P = 0.209) | DEX: 15 (56%) IVB: 10 (44%) (P = 0.571) | DEX: 59 ± 12 IVB: 59 ± 13 (P = 0.770) | DEX: 458 ± 100 IVB: 485 ± 122 (P = 0.508) | 7 |
Gallemore et al. 2017 [26] | California, United States | DR | DEX: 10 IVB: 10 | DEX: Ozurdex, 0.7 mg given at initial visit and at month 4 (visit 5) IVB: 1.25 mg given at initial visit and Q1 month for a total of 5 treatments | NA | DEX: 63.9 ± 1.8 IVB: 61.2 ± 2.9 | DEX: 5 (50%) IVB: 3 (30%) | DEX: 67.8 ± 3.8 IVB: 71.9 ± 2.9 | DEX: 385.9 ± 43.0 IVB: 341.5 ± 11.3 | 6 |